RepliCel Life Sciences Announces Closing of Third and Final Tranche of Private Placement

RepliCel Life Sciences Announces Closing of Third and Final Tranche of Private 
FOR: RepliCel Life Sciences Inc. 
JUNE 17, 2014 
RepliCel Life Sciences Announces Closing of Third and Final Tranche of Private
VANCOUVER, BRITISH COLUMBIA--(Marketwired - June 17, 2014) - RepliCel Life
Sciences Inc. ("RepliCel" or the "Company") (TSX
VENTURE:RP)(OTCQB:REPCF), is pleased to announce it has completed the third and
final tranche of its non-brokered financing (the "Financing")
announced on March 28, 2014, which consisted of a non-brokered private
placement of 866,000 units (each a "Unit") at a price of $0.75 per
Unit for gross proceeds of $649,500 (the "Offering"). The total final
gross proceeds for the Unit offering were $3,990,125.25. Each Unit consists of
one common share of the Company (each, a "Share") and one Share
purchase warrant (the "Warrant"), which will entitle the holder to
purchase one additional Share for a period of two years from the closing of the
private placement at a price of $1.00 per Share during the first year and $1.25
per Share during the second year. This financing was led by Crossover
Healthcare Fund, LLC.  
"This financing puts us in a position to execute on our near-term clinical
initiatives towards the commercialization of RCT-A-01, a treatment for chronic
Achilles tendinosis, RCS-01, a treatment for aging and sun damaged skin and
RCH-01, a treatment for pattern baldness. All three trials are on track for
filing this year which will drive key six month data next year for RCT-A-01 and
RCS-01. Launching three human clinical trials running concurrently will be a
significant accomplishment for a biotech company of our size. To our knowledge,
there are only a handful of publically traded companies in the regenerative
medicine sector that are doing this," stated David Hall, CEO of RepliCel.
He goes on to say, "We are especially excited to have the participation of
Crossover Healthcare Fund LLC in this last tranche of financing. The Crossover
Healthcare Fund, led by Navroze Alphonse and Dr. John P. Nicholson Jr., is a
strategic new life science focused Boston-based shareholder who we look forward
to working with as we rapidly broaden our exposure to the US healthcare
investment community."  
All securities issued in the financing will be subject to a statutory hold
period expiring four months and one day after closing of the financing. None of
the securities issued in the financing have been registered under the United
States Securities Act of 1933, as amended (the "1933 Act"), and none
of them may be offered or sold in the United States absent registration or an
applicable exemption from the registration requirements of the 1933 Act. This
press release shall not constitute an offer to sell or a solicitation of an
offer to buy nor shall there be any sale of the securities in any state where
such offer, solicitation, or sale would be unlawful.  
Further to its news release dated May 9, 2014, the Company also announces that
in connection with the closing of the first tranche of the financing, the
Company issued additional finder's warrants to purchase 42,800 Shares at a
price of $0.75 per Share for a period of 24 months to one finder. 
About RepliCel Life Sciences 
RepliCel is a regenerative medicine company focused on developing autologous
cell therapies that address diseases caused by a deficit of healthy cells
required for normal healing and function such as chronic tendinosis, damaged
skin and pattern baldness. The company's RCT-01 and RCS-01 cell therapies
are designed to treat chronic tendinosis and damaged or aging skin
respectively, using fibroblasts isolated from the sheath of the hair follicle.
Another of the company's pipeline products, RCH-01 for the treatment of
pattern baldness, is manufactured from cells derived from the hair follicle
dermal cup. Shiseido Company, Limited has an exclusive geographic license for
RCH-01 in certain Asian countries including Japan, China and South Korea. All
product candidates are based on RepliCel's innovative technology which
utilizes cells isolated from a patient's own healthy hair follicles to
address specific cellular deficits. For additional information please visit 
Neither the TSX Venture Exchange Inc. nor its Regulation Service Provider (as
that term is defined in the policies of the TSX Venture Exchange Inc.) accepts
responsibility for the adequacy or accuracy of this press release. 
This press release contains forward-looking information that involve various
risks and uncertainties regarding future events, including statements regarding
the Company's belief that the proceeds from the financing puts the Company
in a position to execute on its clinical incentives, the timing of trials, and
the Company broadening its exposure into the US healthcare investment
community. Such forward-looking information can include without limitation
statements based on current expectations involving a number of risks and
uncertainties and are not guarantees of future performance of RepliCel. There
are numerous risks and uncertainties that could cause actual results and
RepliCel's plans and objectives to differ materially from those expressed
in the forward-looking information, including: negative results from the
Company's clinical trials; the effects of government regulation on the
Company's business; risks associated with the Company's ability to
obtain and protect rights to its intellectual property; risks and uncertainties
associated with the Company's ability to raise additional capital; and
other factors beyond the Company's control. Actual results and future
events could differ materially from those anticipated in such information.
These and all subsequent written and oral forward-looking information are based
on estimates and opinions of management on the dates they are made and are
expressly qualified in their entirety by this notice. Except as required by
law, RepliCel does not intend to update these forward-looking statements. 
RepliCel Life Sciences Inc.
David M. Hall
Chief Executive Officer
RepliCel Life Sciences Inc.
Tammey George
Director of Communications
Westwicke Partners, LLC
Robert H. Uhl
Managing Director
Christina Cameron 
INDUSTRY:  Pharmaceuticals and Biotech - Biotech, Pharmaceuticals and Biotech -
-0- Jun/17/2014 12:00 GMT
Press spacebar to pause and continue. Press esc to stop.